Bioline RX Ltd - ADR
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Bioline RX Ltd - ADR
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
/ 
Frequently asked questions
To buy Bioline RX Ltd - ADR stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Bioline RX Ltd - ADR by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Bioline RX Ltd - ADR is BLRX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Bioline RX Ltd - ADR has its primary listing on NASDAQ (Small cap). You can trade Bioline RX Ltd - ADR with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Bioline RX Ltd - ADR is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Bioline RX Ltd - ADR as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Bioline RX Ltd - ADR.